ACUR Acura Pharmaceuticals

Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. Its technology platforms include AVERSION, IMPEDE, and LIMITX. The company was founded on April 10, 1935 and is headquartered in Palatine, IL.
Company profile
Ticker
ACUR
Exchange
Website
CEO
Robert B. Jones
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HALSEY DRUG CO INC/NEW
SEC CIK
Corporate docs
IRS number
110853640
ACUR stock data
()
Investment data
Securities sold
Number of investors
Calendar
16 Nov 20
28 Feb 21
31 Dec 21
Financial summary
Quarter (USD) |
Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 493K | 493K | 493K | 493K | 493K | 493K |
Cash burn (monthly) | 181.67K | (positive/no burn) | 226K | 45.08K | 181.67K | 3.25K |
Cash used (since last report) | 905.25K | n/a | 1.13M | 224.65K | 905.25K | 16.19K |
Cash remaining | -412.25K | n/a | -633.16K | 268.35K | -412.25K | 476.81K |
Runway (months of cash) | -2.3 | n/a | -2.8 | 6.0 | -2.3 | 146.7 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Feb 21 | Peter A Clemens | Common Stock | Payment of exercise | Dispose F | No | No | 0.4 | 15,100 | 6.04K | 416,097 |
24 Feb 21 | Peter A Clemens | Common Stock | Option exercise | Aquire M | No | No | 0.151 | 40,000 | 6.04K | 431,197 |
24 Feb 21 | Peter A Clemens | Stock options Common Stock | Option exercise | Dispose M | No | No | 0.151 | 40,000 | 6.04K | 0 |
24 Feb 21 | James F Emigh | Common Stock | Payment of exercise | Dispose F | No | No | 0.4 | 7,550 | 3.02K | 474,042 |
24 Feb 21 | James F Emigh | Common Stock | Option exercise | Aquire M | No | No | 0.151 | 20,000 | 3.02K | 481,592 |
24 Feb 21 | James F Emigh | Stock options Common Stock | Option exercise | Dispose M | No | No | 0.151 | 20,000 | 3.02K | 0 |
24 Feb 21 | Robert A Seiser | Common Stock | Payment of exercise | Dispose F | No | No | 0.4 | 7,550 | 3.02K | 353,588 |
24 Feb 21 | Robert A Seiser | Common Stock | Option exercise | Aquire M | No | No | 0.151 | 20,000 | 3.02K | 361,138 |
24 Feb 21 | Robert A Seiser | Stock options Common Stock | Option exercise | Dispose M | No | No | 0.151 | 20,000 | 3.02K | 0 |
4 Jan 21 | Robert A Seiser | Common Stock | Payment of exercise | Dispose F | No | No | 0.21 | 10,686 | 2.24K | 341,138 |
Institutional ownership Q4 2020
0.0% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 0 |
Total shares | 1.03K |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|---|---|
Lenox Wealth Advisors | 780 | $0 |
Captrust Financial Advisors | 245 | $0 |
Financial report summary
?Competition
Pfizer • Nektar Therapeutics • Elite Pharmaceuticals • Cassava Sciences • Acelrx Pharmaceuticals • KemPharm • PerrigoContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
alprazolam, imminent, inception, Intermediate, rescinded
Removed:
discounting, optimized
Financial reports
10-Q
2020 Q3
Quarterly report
16 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
28 Jun 20
10-K
2019 FY
Annual report
30 Mar 20
NT 10-K
Notice of late annual filing
30 Mar 20
10-Q
2019 Q3
Quarterly report
28 Feb 20
10-Q
2019 Q2
Quarterly report
10 Feb 20
NT 10-Q
Notice of late quarterly filing
8 Nov 19
10-Q
2019 Q1
Quarterly report
1 Oct 19
10-K
2018 FY
Annual report
16 Sep 19
Current reports
8-K
Acura Pharmaceuticals Announces Third Quarter 2020 Financial Results
17 Nov 20
8-K
Entry into a Material Definitive Agreement
29 Oct 20
8-K
Acura Pharmaceuticals Announces Second Quarter 2020 Financial Results
17 Aug 20
8-K
Acura Pharmaceuticals Announces First Quarter 2020 Financial Results
30 Jun 20
8-K
Other Events
13 May 20
8-K
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
1 Apr 20
8-K
Acura Pharmaceuticals Announces Third Quarter 2019 Financial Results
17 Mar 20
8-K
Acura Pharmaceuticals Announces Second Quarter 2019 Financial Results
12 Feb 20
8-K
Acura Pharmaceuticals Provides an Update
2 Jan 20
8-K
Acura Pharmaceuticals Announces First Quarter 2019 Financial Results
4 Oct 19
Registration and prospectus
RW
Registration withdrawal request
31 Jul 18
S-8
Registration of securities for employees
16 Nov 17
D
$4M in equity / options / securities to be acquired, sold $4M, 1 investor
27 Jul 17
25-NSE
Exchange delisting
13 Mar 17
S-1
IPO registration
2 Feb 17
S-8
Registration of securities for employees
8 Aug 16
S-3/A
Shelf registration (amended)
22 Mar 16
S-3
Shelf registration
8 Mar 16
424B5
Prospectus supplement for primary offering
30 Jun 15
S-8
Registration of securities for employees
30 Apr 14
Proxies
DEF 14A
Definitive proxy
26 Sep 17
DEFA14A
Additional proxy soliciting materials
26 Sep 17
DEFA14A
Additional proxy soliciting materials
12 Apr 16
DEF 14A
Definitive proxy
6 Mar 16
DEFA14A
Additional proxy soliciting materials
6 Mar 16
DEFA14A
Additional proxy soliciting materials
20 Jul 15
DEF 14A
Definitive proxy
13 Jul 15
PRE 14A
Preliminary proxy
21 Jun 15
DEF 14A
Definitive proxy
17 Mar 15
DEFA14A
Additional proxy soliciting materials
17 Mar 15
Other
CT ORDER
Confidential treatment order
9 Apr 18
CT ORDER
Confidential treatment order
14 Jun 17
EFFECT
Notice of effectiveness
29 Mar 16
CORRESP
Correspondence with SEC
24 Mar 16
UPLOAD
Letter from SEC
17 Mar 16
CT ORDER
Confidential treatment order
23 Feb 16
CT ORDER
Confidential treatment order
4 May 15
UPLOAD
Letter from SEC
16 Oct 14
CORRESP
Correspondence with SEC
14 Oct 14
CORRESP
Correspondence with SEC
28 Sep 14
Ownership
4
ACURA PHARMACEUTICALS / Robert A Seiser ownership change
26 Feb 21
4
ACURA PHARMACEUTICALS / JAMES F EMIGH ownership change
26 Feb 21
4
ACURA PHARMACEUTICALS / PETER A CLEMENS ownership change
26 Feb 21
4
ACURA PHARMACEUTICALS / IMMANUEL THANGARAJ ownership change
12 Jan 21
4
ACURA PHARMACEUTICALS / GEORGE K ROSS ownership change
6 Jan 21
4
ACURA PHARMACEUTICALS / BRUCE F WESSON ownership change
6 Jan 21
4
ACURA PHARMACEUTICALS / WILLIAM G SKELLY ownership change
6 Jan 21
4
ACURA PHARMACEUTICALS / Robert A Seiser ownership change
6 Jan 21
4
ACURA PHARMACEUTICALS / Robert B Jones ownership change
6 Jan 21
4
ACURA PHARMACEUTICALS / JAMES F EMIGH ownership change
6 Jan 21
Patents
APP
Utility
Methods and Compositions for Self-regulated Release of Active Pharmaceutical Ingredient
2 Dec 20
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
GRANT
Utility
Methods and compositions for self-regulated release of active pharmaceutical ingredient
22 Jun 20
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
APP
Utility
Methods and Compositions for Interfering with Extraction or Conversion of a Drug Susceptible to Abuse
17 Jun 20
Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
GRANT
Utility
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
6 Apr 20
Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
GRANT
Utility
Methods and compositions for self-regulated release of active pharmaceutical ingredient
14 Oct 19
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.